While there continues to be an almost obsessive and fervant attention and focus on cancer immunotherapy, let’s not forget that chemotherapy and/or targeted therapy combinations are still the standard of care in many cases.
There are also numerous pipeline trials still ongoing and especially in the case of diseases with a low number of somatic mutations, other approaches may continue to have more utility and clinical benefit than say, monotherapy with checkpoint blockade.
So what’s in store in our second ESMO17 Preview series?
Following on from the Top 5 IO abstracts earlier this week, next up in the spotlight is the Targeted Therapy Top 5 Selections…
To learn more insights on this intriguing topic, subscribers can log-in or you can gain access to BSB Premium Content.